Alpha Profiles · Company Profile

4D Molecular Therapeutics, Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/4d-molecular-therapeutics-inc

Entity: Public listing published
Primary listing: NASDAQ: FDMT
Verification: Partially verified
Last reviewed: 2026-09-06T06:32:22.234968+00:00

Overview

Alpha's canonical identity and public leadership record for 4D Molecular Therapeutics, Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

6 public records

Christopher Simms

Chief Commercial and Business Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001140361-26-017427Apr 28, 2026

David Kirn

President and Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001140361-26-017427Apr 28, 2026

David Kirn, M.D.

President, Chief Executive Officer and Director

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: FDMT DEF 14A executive officersApr 28, 2026

Kristian Humer

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001140361-26-017427Apr 28, 2026

Scott Bizily

Chief Legal Officer and Corporate Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001140361-26-017427Apr 28, 2026

Scott Bizily, J.D., Ph.D.

Chief Legal Officer and Corporate Secretary

State: confirmed
Effective: From Apr 28, 2026
Confidence: 94%
Evidence: FDMT DEF 14A executive officersApr 28, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 6, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.